Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048)

Autor: Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G M Hughes, Ricard Mesía, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey-Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gumuscu, Jonathan D Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan Jose Zarba, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Anne Taylor, Martin Burian, Carlos Henrique Barrios, Dalvaro Oliveira de Castro Junior, Gilberto Castro, Fabio Andre Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Santos, Ana-Paula Victorino, Neil Chua, Felix Couture, Richard Gregg, Aaron Hansen, John Hilton, Joy McCarthy, Denis Soulieres, Rodrigo Ascui, Pablo Gonzalez, Luis Villanueva, Marco Torregroza, Angela Zambrano, Petra Holeckova, Zdenek Kral, Bohuslav Melichar, Jana Prausova, Milan Vosmik, Maria Andersen, Niels Gyldenkerne, Hannes Jurgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Dora Kwong, Yousuf Al-Farhat, Tibor Csoszi, Jozsef Erfan, Geza Horvai, Laszlo Landherr, Eva Remenar, Agnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nole, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi, Nobuya Monden, Masahiro Nakayama, Kenji Okami, Nobuhiko Oridate, Kiyoto Shiga, Yasushi Shimizu, Masashi Sugasawa, Masanobu Takahashi, Shunji Takahashi, Kaoru Tanaka, Tsutomu Ueda, Hironori Yamaguchi, Tomoko Yamazaki, Ryuji Yasumatsu, Tomoya Yokota, Tomokazu Yoshizaki, Iveta Kudaba, Zinaida Stara, Soon Keat Cheah, Jose Aguilar Ponce, Rene Gonzalez Mendoza, Carlos Hernandez Hernandez, Francisco Medina Soto, Jan Buter, Ann Hoeben, S. Oosting, Karijn Suijkerbuijk, Aase Bratland, Marianne Brydoey, Renzo Alvarez, Luis Mas, Priscilla Caguioa, John Querol, Eugenio Emmanuel Regala, Maria Belen Tamayo, Ellie May Villegas, Andrzej Kawecki, Andrey Karpenko, Arkadiy Klochikhin, Alexey Smolin, Oleg Zarubenkov, Boon Cher Goh, Graham Cohen, Johanna du Toit, Christa Jordaan, Gregory Landers, Paul Ruff, Waldemar Szpak, Neonyana Tabane, Irene Brana, Lara Iglesias Docampo, Javier Lavernia, Ricard Mesia, Edvard Abel, Valentina Muratidu, Niels Nielsen, Valerie Cristina, Sacha Rothschild, Hung-Ming Wang, Muh-Hwa Yang, Su-Peng Yeh, Chia-Jui Yen, Nopadol Soparattanapaisarn, Virote Sriuranpong, Sercan Aksoy, Irfan Cicin, Meltem Ekenel, Hakan Harputluoglu, Ozgur Ozyilkan, Kevin Harrington, Sanjiv Agarwala, Haythem Ali, Robert Alter, Daniel Anderson, Justine Bruce, Nicholas Campbell, Miguel Conde, John Deeken, William Edenfield, Lawrence Feldman, Elizabeth Gaughan, Basem Goueli, Balazs Halmos, Upendra Hegde, Brian Hunis, Robert Jotte, Anand Karnad, Saad Khan, Noel Laudi, Douglas Laux, Danko Martincic, Steven McCune, Dean McGaughey, Krzysztof Misiukiewicz, Deborah Mulford, Eric Nadler, Johannes Nunnink, James Ohr, Meaghan O'Malley, Brian Patson, Doru Paul, Elizabeta Popa, Steven Powell, Rebecca Redman, Vincent Rella, Chaio Rocha Lima, Abirami Sivapiragasam, Yungpo Su, Ammar Sukari, Stuart Wong, Emrullah Yilmaz, Jeffrey Yorio

Publikováno v: The Lancet, 394(10212), 1915-1928. ELSEVIER SCIENCE INC

BACKGROUND: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response.METHODS: KEYNOTE-048 was a randomised, phase 3 study of participants with u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b09cca112b6c7ad9036b0332984d6f1
https://research.rug.nl/en/publications/20397cd6-a956-4739-9a91-2e8cc9ca248f

Selection of systemic therapy in patients with locally advanced and recurrent/metastatic head and neck cancer: RAND-based expert opinion by an Italian multidisciplinary panel

Autor: Stefano Maria Magrini, Graziana Ronzino, Marco Merlano, Michela Buglione, Lisa Licitra, Marco Benasso, Livio Presutti, Pierluigi Bonomo, Maria Grazia Ghi, Daris Ferrari

Background: Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease often presenting at an already advanced stage. Cisplatin chemoradiotherapy is the standard treatment for locally advanced disease, although its efficacy varies accor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c76d7cea46eb4201bf7d4fadbc73798
https://hdl.handle.net/11380/1188913

Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study

Autor: Chiara Molinelli, Sergio Bertoglio, Matteo Lambertini, Francesco Boccardo, Chiara Dellepiane, Piero Fregatti, Lucia Del Mastro, Giulia Buzzatti, S. Pastorino, Francesca Poggio, Benedetta Conte, Alessia Levaggi, Andrea Michelotti, Claudia Bighin, Alessia D’ Alonzo, Eva Blondeaux, Marco Benasso

Publikováno v: British Journal of Cancer

Background Adjuvant chemotherapy is the standard of care in high-risk early breast cancer patients. Dose-dense should be the preferred schedule of administration. However, its long-term benefit is unknown. Methods In the Italian multicentre Phase 3 r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a251c319a09de9c1786bc848c8213b
https://pubmed.ncbi.nlm.nih.gov/32231293

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Autor: Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan Cheng, Ramona F Swaby, Kevin J Harrington, Mirelis Acosta-Rivera, Douglas R. Adkins, Morteza Aghmesheh, Mario Airoldi, Eduardas Aleknavicius, Yousuf Al-Farhat, Alain P. Algazi, Salah Almokadem, Anna Alyasova, Jessica R. Bauman, Marco Benasso, Alfonso Berrocal, Victoria Bray, Barbara Ann Burtness, Francesco Caponigro, Ana Castro, Terrence P. Cescon, Kelvin Chan, Arvind Chaudhry, Bruno Chauffert, Ezra Cohen, Tibor Csoszi, J.P. De Boer, Jean-Pierre Delord, Andreas Dietz, Jose Dinis, Charlotte Dupuis, Laurence Digue, Jozsef Erfan, Yolanda Escobar Alvarez, Mererid Evans, Mary Jo Fidler, Martin David Forster, Signe Friesland, Apar K. Ganti, Lionnel Geoffrois, Cliona Grant, Viktor Gruenwald, Kevin Harrington, Thomas Hoffmann, Geza Horvai, Arturas Inciura, Raymond Jang, Petra Jankowska, Antonio Jimeno, Mano Joseph, Alejandro Juarez Ramiro, Boguslawa Karaszewska, Andrzej Kawecki, Ulrich Keilholz, Ulrich Keller, Sung-Bae Kim, Judit Kocsis, Nuria Kotecki, Mark F. Kozloff, Julio Lambea, Laszlo Landherr, Yuri Lantsukhay, Sergey Alexandrovich Lazarev, Lip Way Lee, Igor Dmitrievich Lifirenko, Danko Martincic, Oleg Vladmirovhich Matorin, Margaret McGrath, Krzysztof Misiukiewicz, John C. Morris, Fagim Fanisovich Mufazalov, Jiaxin Niu, Devraj Pamoorthy Srinivasan, Pedro Perez Segura, Daniel Rauch, Maria Leonor Ribeiro, Cristina Rodriguez, Frederic Rolland, Antonio Russo, Agnes Ruzsa, Frederico Sanches, Sang-Won Shin, Mikhail Shtiveland, Denis Soulieres, Pol Specenier, Eva Szekanecz, Judit Szota, Carla M.L. van Herpen, Hector A. Velez-Cortes, William V. Walsh, Stefan Wilop, Ralph Winterhalder, Marek Wojtukiewicz, Deborah Wong, Dan Zandberg

Publikováno v: The Lancet, Vol. 393, No 10167 (2019) pp. 156-167
The lancet : international edition
Lancet, Vol. 393, no. 10167, p. 156-167 (2019)

Summary Background There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. We aimed to compare

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2fa1f3e2ce98a5be2c51dc208c21406
https://archive-ouverte.unige.ch/unige:155811

Das Problem des Übels: Allgemeine Bemerkungen

Autor: Marco Benasso

Publikováno v: Evolution und Leid als Herausforderung für den Glauben ISBN: 9783658224332

Freilich nimmt der Umgang mit dem Problem des Ubels unterschiedliche Formen an, je nachdem in welchem philosophischen und weltanschaulichen Rahmen es formuliert wird. Neben unterschiedlichen Formulierungen, die Argumente aus dem Ubel annehmen konnen,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e7cb8ff4eabd03f5c6cbf1740745bdc2
https://doi.org/10.1007/978-3-658-22434-9_2